Blood Fingerprint Identification System BloodID Pilots at Mayo Clinic: Classifying 12 Cancer Types From a Single Blood Draw

Mayo Clinic and PathAI announced on December 3 that their collaborative blood fingerprint identification system BloodID has entered the clinical validation stage. BloodID constructs a unique "blood fingerprint" for each tumor type by analyzing circulating tumor DNA's fragment length distribution, end-sequence features, and methylation patterns in the blood, completing tissue-of-origin localization and molecular subtyping for 12 common solid tumors from a single blood tube.

In initial data from 500 patients, BloodID achieved 89% accuracy in identifying tumor tissue of origin and 82% accuracy in molecular subtyping. Mayo Clinic's oncology director said BloodID has the potential to reduce cancer diagnosis time from an average of 6 weeks to 3 days, while avoiding approximately 40% of invasive tissue biopsies.